Summit Short Long Term Debt Total vs Total Assets Analysis

SMMT Stock  USD 18.77  0.80  4.45%   
Summit Therapeutics financial indicator trend analysis is much more than just breaking down Summit Therapeutics PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Summit Therapeutics PLC is a good investment. Please check the relationship between Summit Therapeutics Short Long Term Debt Total and its Total Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Short Long Term Debt Total vs Total Assets

Short Long Term Debt Total vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Summit Therapeutics PLC Short Long Term Debt Total account and Total Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Summit Therapeutics' Short Long Term Debt Total and Total Assets is 0.97. Overlapping area represents the amount of variation of Short Long Term Debt Total that can explain the historical movement of Total Assets in the same time period over historical financial statements of Summit Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Summit Therapeutics' Short Long Term Debt Total and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt Total of Summit Therapeutics PLC are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Short Long Term Debt Total i.e., Summit Therapeutics' Short Long Term Debt Total and Total Assets go up and down completely randomly.

Correlation Coefficient

0.97
Relationship DirectionPositive 
Relationship StrengthVery Strong

Short Long Term Debt Total

Total Assets

Total assets refers to the total amount of Summit Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Summit Therapeutics PLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Summit Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Summit Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
At this time, Summit Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 35.83 in 2024, whereas Tax Provision is likely to drop (25.4 K) in 2024.
 2021 2022 2023 2024 (projected)
Interest Expense281K4.4M16.5M17.3M
Depreciation And Amortization2.5M2.5M90.7M95.3M

Summit Therapeutics fundamental ratios Correlations

0.680.770.760.710.82-0.48-0.240.970.10.20.020.96-0.310.390.970.920.530.981.00.32-0.190.970.25-0.130.21
0.680.750.660.860.44-0.710.110.570.440.270.150.75-0.320.620.570.430.750.610.660.66-0.120.57-0.010.230.5
0.770.750.770.590.35-0.360.260.780.550.380.310.7-0.480.210.670.650.410.710.740.76-0.420.64-0.050.450.03
0.760.660.770.660.33-0.44-0.060.780.470.460.260.75-0.440.330.610.610.510.640.740.5-0.290.620.330.260.14
0.710.860.590.660.53-0.93-0.180.570.220.30.130.87-0.370.860.610.40.960.630.70.37-0.10.610.44-0.060.76
0.820.440.350.330.53-0.4-0.470.74-0.36-0.15-0.240.790.020.380.90.820.410.880.84-0.060.120.910.22-0.560.3
-0.48-0.71-0.36-0.44-0.93-0.40.15-0.29-0.19-0.34-0.09-0.70.28-0.96-0.38-0.12-0.99-0.4-0.47-0.27-0.02-0.38-0.530.17-0.92
-0.240.110.26-0.06-0.18-0.470.15-0.250.630.320.06-0.28-0.25-0.16-0.32-0.3-0.13-0.28-0.280.73-0.33-0.35-0.440.74-0.18
0.970.570.780.780.570.74-0.29-0.250.10.190.060.88-0.30.190.950.960.350.960.970.29-0.230.950.19-0.070.0
0.10.440.550.470.22-0.36-0.190.630.10.680.460.12-0.40.09-0.07-0.070.24-0.020.040.8-0.37-0.09-0.150.680.02
0.20.270.380.460.3-0.15-0.340.320.190.680.350.27-0.040.260.070.030.360.10.160.450.050.060.320.240.11
0.020.150.310.260.13-0.24-0.090.060.060.460.350.02-0.12-0.11-0.08-0.050.12-0.05-0.010.16-0.24-0.070.20.46-0.08
0.960.750.70.750.870.79-0.7-0.280.880.120.270.02-0.360.620.910.780.740.920.950.3-0.160.910.4-0.20.47
-0.31-0.32-0.48-0.44-0.370.020.28-0.25-0.3-0.4-0.04-0.12-0.36-0.25-0.21-0.15-0.33-0.24-0.29-0.420.93-0.18-0.08-0.3-0.22
0.390.620.210.330.860.38-0.96-0.160.190.090.26-0.110.62-0.250.310.050.940.330.390.180.060.310.47-0.260.94
0.970.570.670.610.610.9-0.38-0.320.95-0.070.07-0.080.91-0.210.310.960.421.00.980.2-0.121.00.19-0.270.15
0.920.430.650.610.40.82-0.12-0.30.96-0.070.03-0.050.78-0.150.050.960.180.950.930.16-0.140.960.08-0.19-0.12
0.530.750.410.510.960.41-0.99-0.130.350.240.360.120.74-0.330.940.420.180.450.520.31-0.040.420.52-0.120.9
0.980.610.710.640.630.88-0.4-0.280.96-0.020.1-0.050.92-0.240.331.00.950.450.990.25-0.150.990.18-0.220.16
1.00.660.740.740.70.84-0.47-0.280.970.040.16-0.010.95-0.290.390.980.930.520.990.27-0.170.980.26-0.170.21
0.320.660.760.50.37-0.06-0.270.730.290.80.450.160.3-0.420.180.20.160.310.250.27-0.350.17-0.30.660.07
-0.19-0.12-0.42-0.29-0.10.12-0.02-0.33-0.23-0.370.05-0.24-0.160.930.06-0.12-0.14-0.04-0.15-0.17-0.35-0.090.07-0.410.07
0.970.570.640.620.610.91-0.38-0.350.95-0.090.06-0.070.91-0.180.311.00.960.420.990.980.17-0.090.21-0.30.16
0.25-0.01-0.050.330.440.22-0.53-0.440.19-0.150.320.20.4-0.080.470.190.080.520.180.26-0.30.070.21-0.330.46
-0.130.230.450.26-0.06-0.560.170.74-0.070.680.240.46-0.2-0.3-0.26-0.27-0.19-0.12-0.22-0.170.66-0.41-0.3-0.33-0.32
0.210.50.030.140.760.3-0.92-0.180.00.020.11-0.080.47-0.220.940.15-0.120.90.160.210.070.070.160.46-0.32
Click cells to compare fundamentals

Summit Therapeutics Account Relationship Matchups

Summit Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets96.9M102.5M113.4M664.2M202.9M213.1M
Other Current Liab6.2M5.0M12.2M17.0M14.9M15.7M
Total Current Liabilities12.7M19.9M25.6M38.8M20.4M11.0M
Total Stockholder Equity78.5M79.5M83.3M126.7M77.7M39.6M
Property Plant And Equipment Net1.5M1.3M3.5M5.1M6.1M6.4M
Net Debt(63.2M)(66.0M)(69.0M)170.2M34.7M36.4M
Retained Earnings(125.3M)(214.7M)(299.5M)(378.3M)(993.3M)(943.6M)
Accounts Payable4.5M6.1M4.4M355K2.7M4.2M
Cash64.1M66.4M71.8M348.6M71.4M47.0M
Non Current Assets Total17.1M36.1M16.1M7.5M13.2M12.3M
Non Currrent Assets Other4.2M21.3M170K577K5.3M5.5M
Other Assets1.0(16.4M)25.5M577K663.6K710.0K
Cash And Short Term Investments64.1M66.4M71.8M348.6M186.2M195.6M
Common Stock Shares Outstanding164.1M69.5M92.2M193.3M619.6M650.6M
Liabilities And Stockholders Equity96.9M102.5M113.4M664.2M202.9M213.1M
Non Current Liabilities Total5.7M3.2M4.5M498.7M104.9M110.1M
Other Current Assets8.8M11.1M1.2M302.0M2.6M2.5M
Other Stockholder Equity171.0M293.4M384.0M504.8M1.1B1.1B
Total Liab18.4M23.0M30.1M537.5M125.3M131.5M
Total Current Assets79.7M66.4M97.3M656.7M189.7M199.2M
Accumulated Other Comprehensive Income28.3M(3.8M)(2.2M)(1.9M)(2.4M)(2.3M)
Intangible Assets13.9M9.9M11.5M10.4M12.0M7.4M
Common Stock4.4M826K980K2.1M7.0M4.7M
Short Long Term Debt Total898.2K465K2.8M518.8M106.1M111.4M
Current Deferred Revenue4.4M1.5M8.4M7.9M14.2M14.9M
Net Receivables6.8M10.2M17.2M349K848K805.6K
Inventory2.0(11.7M)7.2M301.5M2.4M2.3M
Property Plant And Equipment Gross1.2M1.3M6.9M6.4M7.1M7.5M
Short Term Debt474.3K390K1.1M21.5M2.8M4.0M
Good Will2.4M2.0M2.0M1.8M1.9M3.6M
Property Plant Equipment1.2M1.3M3.5M5.1M5.8M6.1M
Other Liab4.0M3.1M2.8M1.4M1.3M1.2M
Net Tangible Assets47.5M23.4M70.9M124.9M143.6M150.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.